These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19729826)

  • 41. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.
    Cheng K; Chen Y; Li LH; Liu JY
    J Cancer Res Ther; 2013; 9(4):727-9. PubMed ID: 24518728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
    Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
    J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
    Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
    Zhu LM; Zhao YZ; Ju HX; Liu LY; Chen L; Liu BX; Xu Q; Luo C; Ying JE; Yang YS; Zhong HJ
    Asian Pac J Cancer Prev; 2014; 15(16):6559-64. PubMed ID: 25169487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Afonso S; Viani G; Afonso V; Stefano E; Afonso S
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of CEA to predict the effect of chemotherapy with bevacizumab].
    Sasaki S; Ishimaru M; Suzuki H; Ogawa M; Sato Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):463-7. PubMed ID: 20332684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
    Park LC; Lee HS; Shin SH; Park SJ; Park MI; Oh SY; Kwon HC; Baek JH; Choi YJ; Kang MJ; Kim YS
    World J Gastroenterol; 2012 Mar; 18(10):1104-9. PubMed ID: 22416186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
    Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
    Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
    Grothey A; Marshall JL
    Oncology (Williston Park); 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8. PubMed ID: 17536342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
    Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
    Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
    Wang Z; Liang L; Yu Y; Wang Y; Zhuang R; Chen Y; Cui Y; Zhou Y; Liu T
    Cell Physiol Biochem; 2016; 39(3):1239-46. PubMed ID: 27595400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
    Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
    Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
    Shitara K; Matsuo K; Takahari D; Yokota T; Inaba Y; Yamaura H; Sato Y; Najima M; Ura T; Muro K
    Eur J Cancer; 2009 Jul; 45(10):1757-63. PubMed ID: 19217278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
    Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
    Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
    Huang CW; Yeh YS; Ma CJ; Tsai HL; Chen CW; Huang MY; Lu CY; Wu JY; Wang JY
    Chemotherapy; 2017; 62(1):80-84. PubMed ID: 27654129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
    Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
    de Melo JV; Vieira de Melo MS; Abad MH
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.